文献速递脑血管病

2005至2021年丹麦缺血性卒中二级预防药物使用趋势

Trends in the Use of Medications for Secondary Ischemic Stroke Prevention in Denmark, 2005-2021.
PubMed 文献 · Neurology · 2024-04-22

基于丹麦全国登记数据,纳入150,744例首次或复发性缺血性卒中出院患者,按日历年评估出院后180天内降脂、降压、降糖、口服抗凝及抗血小板药物的处方填写概率。2005至2021年间降脂、降糖及口服抗凝药使用上升,降压药与抗血小板药保持稳定;高龄、重症及合并神经精神疾病者总体用药较低。

要点

  • 2005至2021年降脂药使用从58.3%升至82.0%,阿托伐他汀从2.1%升至64.8%,辛伐他汀从55.7%降至8.6%。
  • 口服抗凝药从45.9%升至87.0%,主要因直接口服抗凝药自2010年前后增加及华法林使用下降。
  • 降压药稳定在约89%,抗血小板药持续约95%;高龄、重症及合并症患者总体用药较低。

核心结论

  • 5类药物中3类使用呈上升趋势,但降脂、降糖及口服抗凝药总体使用略低于临床指南预期,尤其在高龄、重症及合并其他疾病的患者中。
  • 上述亚组用药相对较低可能反映在频繁禁忌证与预期寿命缩短下的合理临床决策,也可能提示近期缺血性卒中患者照护中存在可改进之处。

研究设计与样本

  • 基于丹麦全国登记数据的队列研究,纳入出院时诊断为首次或复发性缺血性卒中的患者N=150,744例。
  • 按日历年分层,评估出院后180天内填写上述药物处方的概率,并分析与用药相关的因素。

主要发现

  • 2005至2021年降脂药使用从58.3%升至82.0%;阿托伐他汀从2.1%升至64.8%,辛伐他汀从55.7%降至8.6%。
  • 降压药使用保持稳定,约89%,各类降压药使用相当。
  • 降糖药从2005年71.5%升至2021年84.1%,主要由二甲双胍从28.0%升至59.5%驱动。
  • 2015至2021年间胰高血糖素样肽-1受体激动剂从1.7%升至17.5%,钠-葡萄糖协同转运蛋白-2抑制剂从0.5%升至17.3%。
  • 抗凝药从2005年45.9%升至2021年87.0%,主要因直接口服抗凝药自2010年前后增加及华法林下降;抗血小板药持续约95%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Understanding trends in the use of medications for secondary stroke prevention is crucial for identifying areas for improvement in stroke care. We examined the use of lipid-lowering, antihypertensive, glucose-lowering, oral anticoagulant, and antiplatelet medications after ischemic stroke hospitalization, from 2005 to 2021. METHODS: Using nationwide registries in Denmark, we identified a cohort of patients discharged from hospital with a first-time or recurrent ischemic stroke (N = 150,744). Stratified by calendar year, we ascertained the 180-day probability of filling a prescription for the abovementioned medications after discharge. We further assessed factors associated with medication use. RESULTS: From 2005 to 2021, lipid-lowering medication use increased from 58.3% to 82.0%; atorvastatin use rose from 2.1% to 64.8% and simvastatin use decreased from 55.7% to 8.6%. Antihypertensive medication use remained stable, at approximately 89%, and various antihypertensive classes were used comparably. Glucose-lowering medication use increased from 71.5% in 2005 to 84.1% in 2021, driven primarily by an increase in metformin use (from 28.0% to 59.5%). Use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors continually increased (from 1.7% to 17.5% and from 0.5% to 17.3%, respectively) between 2015 and 2021. Anticoagulant medication use rose from 45.9% in 2005 to 87.0% in 2021, primarily because of increased use of direct oral anticoagulant medications starting around 2010 and a decline in warfarin use. Antiplatelet use remained consistently high, at approximately 95%. Trends were consistent across subgroups of interest; however, overall medication use was lower in older patients (65 years and older), patients with severe stroke, and patients with neurologic and psychiatric comorbidities. DISCUSSION: Despite increasing trends in the use of 3 of 5 medication classes, the overall use of lipid-lowering, glucose-lowering, and oral anticoagulant medications was somewhat lower than expected according to clinical guidelines, particularly among older patients with more severe stroke and other comorbidities. The relatively low use in these subgroups may signify appropriate clinical decision making in consideration of frequent contraindications and reduced life expectancy or highlight potential areas of improvement for the care of patients with recent ischemic stroke.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Skajaa N, Laugesen K, Lauffenburger JC, et al. Trends in the Use of Medications for Secondary Ischemic Stroke Prevention in Denmark, 2005-2021. Neurology. 2024. PMID: 38648572. doi:10.1212/WNL.0000000000209309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。